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Abstract
Background: Survivin and its alternative splice forms are involved in critical cellular processes,
including cell division and programmed cell death. Survivin is expressed in the majority of human
cancers, but minimally in differentiated normal tissues. Expression levels correlate with tumor
aggressiveness and resistance to therapy.
Results: In the present study, we identify and characterize a novel survivin isoform that we
designate survivin 2α . Structurally, the transcript consists of 2 exons: exon 1 and exon 2, as well
as a 3' 197 bp region of intron 2. Acquisition of a new in-frame stop codon within intron 2 results
in an open reading frame of 225 nucleotides, predicting a truncated 74 amino acid protein. Survivin
2α  is expressed at high levels in several malignant cell lines and primary tumors. Functional assays
show that survivin 2α  attenuates the anti-apoptotic activity of survivin. Subcellular localization and
immunoprecipitation of survivin 2α  suggests a physical interaction with survivin.
Conclusion: We characterized a novel survivin splice variant that we designated survivin 2α . We
hypothesize that survivin 2α  can alter the anti-apoptotic functions of survivin in malignant cells.
Thus survivin 2α  may be useful as a therapeutic tool in sensitizing chemoresistant tumor cells to
chemotherapy.
Background
Alternative splicing is estimated to occur in 40–60% of all
human genes, accounting for some of the discrepancies
between the large number of known proteins and the
three-fold lower number of human genes in the genome.
Alternative splicing generates a multitude of isoforms that
have overlapping but distinct functions during embryonic
development and that also contribute to maintaining
homeostasis in adult differentiated tissues (reviewed in
[1]). Alternative splice forms of key proteins in cancer,
TP53, MDM2 [2] and c-MYC [3], have been shown to play
a role in oncogenesis.
Survivin was originally identified by structural homology
to IAPs in human B-cell lymphoma [4]. It is composed of
a single BIR domain and an extended carboxy-terminal
coiled coil domain [5]. Transcription from the Survivin
locus gives rise to alternatively spliced transcripts identi-
fied in both human and mice [6-8]. To date, three alterna-
tively spliced isoforms have been described in humans [6-
8]. Survivin-2B is generated by the insertion of an alterna-
tive exon, exon 2B; Survivin-∆  Ex3 arises from the removal
of exon 3 resulting in a frameshift and translation of part
of the 3'UTR generating a unique carboxy-terminus; Sur-
vivin-3B results from the introduction of a novel exon 3B
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resulting in a frameshift and premature termination of the
protein (Figure 1A).
Survivin has 2 main functions; one as a chromosomal pas-
senger protein [9] and the other as an inhibitor of apop-
tosis [10]. Survivin 2B has been shown to be a pro-
apoptotic protein that sensitizes resistant leukemia cells to
chemotherapy in a p53-dependent fashion [11]. Survivin-
∆  Ex3 functions as an anti-apoptotic protein and is upreg-
ulated in malignancies (Mahotka et al., 1999). No func-
tion has yet been described for survivin-3B.
In this report we identify and characterize a novel isoform
of survivin, survivin 2α . We show that survivin 2α  is
expressed at high levels in malignant cells, co-localizes
with survivin and has the potential to attenuate the anti-
apoptotic effect of survivin.
Results and Discussion
Structural Characteristics of Survivin 2α
In this work, we characterized a novel isoform of the sur-
vivin locus. We surveyed the aligned survivin EST
sequences available in the UCSC Human Genome
Structural analysis of survivin 2α  compared with the other human survivin isoforms Figure 1
Structural analysis of survivin 2α  compared with the other human survivin isoforms. A: The survivin pre-mRNA generates at 
least five mature mRNA transcripts. Boxes represent exons, with the sizes indicated below. The size of the additional nucle-
otide sequences for survivin 3B and survivin 2α  are shown. In survivin 2α , 197nt of intron 2 are added, of which 195nt are non-
coding. Protein domains and motifs are indicated above the diagrams. The black arrow indicates the stop codon; the coiled-coil 
domain is shown by the dotted line; and the double lines represent the BIR domain. B: Survivin 2α  transcript and predicted 
protein sequence. The sequence for the survivin 2α  transcript was obtained by sequencing the insert contained within the 
IMAGE clone. C: Predicted 3D structural modeling of survivin 2α  and survivin. The amino acid sequence of survivin 2α  was 
used with SWISS-MODEL to predict a 3D structure by homology modeling. The resulting PDB file was visualized and manipu-
lated using Swiss PBD-Viewer for the view presented. The 3D structure for survivin was obtained from Swiss-PROT database 
(PDB entry 1F3H). The yellow arrows indicate regions of differences between survivin 2α  and survivin. The red arrows repre-
sent the first 2 alpha helices of the BIR domain, and the pink arrow represents the 3rd helix, that is absent in survivin 2α . The 
green arrow points to the C-terminal coiled-coil domain. D: Protein Analysis of survivin 2α . Total HeLa cell lysate was loaded 
on a 18% SDS-PAGE and transferred into nitrocellulose membrane. The proteins were detected by immunoprobing with a pol-
yclonal survivin antibody. A protein of approximate molecular weight 8.5 kDa, corresponding to the predicted size of survivin 
2α  is detected in HeLa cell lysates.Molecular Cancer 2005, 4:11 http://www.molecular-cancer.com/content/4/1/11
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Browser and identified an EST from a human breast tumor
cDNA library (I.M.A.G.E. clone 1631662). We sequenced
the entire cDNA and designated it Survivin 2α . The com-
plete cDNA sequence is shown in Figure 1B. The protein
contains the coding sequences from exon 1 and exon 2,
and one additional amino acid before termination (Figure
1B). This 74 amino acid protein, with a predicted molec-
ular weight of 8.5 kDa, contains a truncated BIR domain
and lacks the carboxy-terminal coiled-coil domain in its
entirety (Figure 1A). There are no defined localization sig-
nals in the protein, and PSORTII predicts localization
within the nucleus and the cytoplasm (Table 1). Align-
ment with the known human survivin isoforms shows
that the sequence of Survivin 2α  is identical to exons 1
and 2 of the other survivin splice variants, with the excep-
tion of the last amino acid. Alignment of Survivin 2α  with
the three mouse survivin isoforms also reveals some sim-
ilarity with survivin40, a 40-amino acid mouse splice var-
iant (not shown). The 3D predicted structure of Survivin
2α  shows the absence of the alpha-helical coiled-coil
domain, present in survivin (Figure 1C). It also shows
minor predicted rearrangements in the structure that may
occur to stabilize the protein (Figure 1C, yellow arrows).
These re-arrangements occur within the BIR domain, and
could have functional implications for the role of Survivin
2α  in apoptosis.
The BIR domain has been shown to be important for
homodimerization and coordination of the zinc atom co-
factor [12]. In the survivin protein, Histidine 80 (H80) is
required for zinc atom coordination and homodimeriza-
tion. Expression constructs containing mutations at this
residue within the Survivin protein have previously been
shown to accelerate PCD (Programmed Cell Death) in
vitro. Similarly, mutations in Cytosine 84 (C84) enhance
PCD, as a result of displacement of the wild type Survivin
protein [13]. The Survivin 2α  protein, truncated at amino
acid 74, lacks both of these amino acid residues. Addition-
ally, Survivin 2α  lacks the third alpha helix in the BIR
domain. As the anti-apoptotic function of Survivin is
mediated both by the BIR domain and by the interaction
of its C-terminal coiled coil domain with microtubules of
the mitotic spindle [10,14,15], it would be predicted that
Survivin 2α  might not have anti-apoptotic properties.
Survivin 2α  is highly expressed in tumor cells
Survivin is critical for global normal embryonic develop-
ment, as demonstrated by the early embryonic lethality of
mice with homozygous deletions in the survivin gene
locus [16]. Survivin proteins are virtually absent from
most normal differentiated tissues, however these pro-
teins are expressed in certain highly proliferative areas
within normal tissues [17-19]. In contrast, survivin is
highly expressed in the majority of human malignancies,
derived from different cell origins. We evaluated the
expression of survivin 2α  in 7 different cancer cell lines, 2
non-transformed tissues and 7 primary medulloblastoma
tumors by quantitative PCR. We designed primers that
will specifically amplify Survivin 2α  after selection of
polyadenylated RNA. Survivin 2α  expression in tumor
cells and primary medulloblastoma tumors varied from
2–100 fold above non transformed cells (Table 2). The
Table 1: Table of the predicted localization and structural 
features of survivin and the novel isoform survivin 2α .
Localization Survivin Survivin 2α
Cytoplasm 56.5% 39.1%
Nucleus 17.4% 34.8%
Cytoskeleton 0% 4.3%
Golgi Apparatus 0% 0%
Plasma membrane 4.3% 0%
ER 4.3% 4.3%
Peroxysome 0% 0%
Mitochondria 13.0% 13.0%
Lysosomes 4.3% 4.3%
Features
BIR 1 Partial
Coiled-Coil 1 0
Protein Size 142 aa 74 aa
Predicted Molecular Weight 16.4 kDa 8.5 kDa
Table 2: Survivin 2α  expression (relative to normal tissue).
Cell Type Relative Increase
Normal Cerebellum 1.00
Normal Breast (MCF10A) 0.97
Breast Carcinoma (MCF7) 8.17
Osteosarcoma (U2OS) 39.06
Lung (A549) 3.03
ALL (Jurkat) 1.84
Soft Tissue Sarcoma (RH28) 94.90
Cervical Carcinoma (HeLa) 58.22
Medulloblastoma (Daoy) 34.23
Primary Tumors
Medulloblastoma #1 4.68
Medulloblastoma #2 154.55
Medulloblastoma #3 93.24
Medulloblastoma #4 5.69
Medulloblastoma #5 8.54
Medulloblastoma #6 9.81
Medulloblastoma#7 75.10Molecular Cancer 2005, 4:11 http://www.molecular-cancer.com/content/4/1/11
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levels of Survivin 2α  transcripts are comparable to those
of Survivin ∆ Exon3 (Table 3). Like Survivin, Survivin 2α  is
expressed at increased levels in transformed cells com-
pared to non-transformed cells, and therefore it suggests
that it could have a role in tumorigenesis. Additionally,
we detected expression of endogenous Survivin 2α  pro-
tein in HeLa cells, suggesting that the transcript is trans-
lated (Figure 1D).
Functional Properties of Survivin 2α
To characterize a function for Survivin 2α , we transfected
Daoy cells with Survivin 2α  and a combination of Sur-
vivin 2α  and Survivin. To induce apoptosis in the Daoy
cells, we treated them with 2 µM of the chemotherapeutic
agent vincristine. Vincristine is a vinca alkaloid that binds
to tubulin, inhibiting microtubule polymerization. It kills
Daoy cells in culture by PCD. We analyzed early apoptotic
events in vincristine-treated transfected cells by Annexin V
staining. Survivin 2α  antagonized the anti-apoptotic effect
of Survivin in co-transfection assays with or without a cell
death stimulus (not shown and Figure 2A). As inhibition
of apoptosis by Survivin involves activation of the caspase
pathway [20], we assayed Survivin 2α  transfected cells for
caspase 3 activation. Caspase-3 was strongly activated in
vector control and Survivin 2α  transfected cells in the
presence of vincristine. Much lower levels of caspase-3
activation were observed in Survivin-transfected cells (Fig-
ure 2B). In the absence of an apoptotic stimulus we
observed a 35% increase of caspase-3 activity in Survivin
2α  cells, as well as a 46% increase in early apoptosis, as
assessed by Annexin V staining. We also performed elec-
tron microscopy analysis of Survivin 2α  transfected and
non-transfected cells. We sorted transfected cells from
non-transfected cells by FACS based on GFP fluorescence,
and processed each population for EM analysis (Figure
2C). Overall, there was a 43% increase in incidence of
apoptosis in Survivin 2α -expressing cells versus non-
expressing cells. Our results suggest that Survivin 2α  can
attenuate survivin's anti-apoptotic activity and sensitize
tumor cells to chemotherapy. These findings have
important therapeutic implications in the treatment of
chemoresistant tumors.
Survivin 2α  alters the subcellular localization of survivin
To characterize the subcellular localization of survivin 2α
we performed direct fluorescence assays in HeLa cells
transfected with a GFP- survivin 2α  construct. Survivin 2α
localized to the nucleus and the cytoplasm in interphase
cells (Figure 3A). In cells undergoing mitosis, survivin 2α
was confined to the cytoplasmic compartment (Figure
3B). Interestingly, when co-expressed with survivin, sur-
vivin 2α  co-localized with survivin to the centromeres of
the chromosomes in prometaphase (Figure 3C) and
metaphase (Figure 3D), and at the midbody during late
telophase/cytokinesis (Figure 3E). Moreover, the normal
cytoplasmic localization of survivin shifted to the nucleus
in interphase cells. This data suggests a direct interaction
between the two proteins, as well as a potential
mechanism for the attenuation of survivin's anti-apop-
totic activity by survivin 2α .
Survivin 2α  physically interacts with survivin
To further investigate the possibility that survivin 2α  inter-
acts with survivin we performed co-immunoprecipitation
experiments. We co-transfected HeLa cells with constructs
encoding a Flag-survivin fusion protein and a myc-sur-
vivin 2α  fusion protein. We used a Flag antibody to pre-
cipitate protein complexes, and a myc antibody to detect
myc-tagged survivin 2α . We detected survivin 2α -myc in
the complexes precipitated with the Flag antibody, sub-
stantiating a physical interaction of survivin with survivin
2α  (Figure 4).
Conclusion
We characterized a novel survivin splice variant that we
designated survivin 2α . We hypothesize that survivin 2α
can alter the anti-apoptotic functions of survivin in malig-
nant cells. Thus, survivin 2α  may be useful as a
therapeutic tool in sensitizing chemoresistant tumor cells
to chemotherapy.
Methods
Patient samples
Seven fresh frozen primary medulloblastoma tumor sam-
ples were obtained from the Cooperative Human Tumor
Network (CHTN), after approval through the Columbus
Children's Hospital IRB.
Table 3: Expression of survivin splice variants in medulloblastoma (relative to survivin)
Tissue Survivin 2B Survivin ∆ Ex3 Survivin 2α
Medulloblastoma #3 37.63 0.46 0.36
Medulloblastoma #4 43.82 0.18 0.18
Medulloblastoma (Daoy) 1290.16 35.10 0.66Molecular Cancer 2005, 4:11 http://www.molecular-cancer.com/content/4/1/11
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Sequencing
IMAGE clone 1631662 (Invitrogen) was sequenced using
primers that flanked the multiple-cloning-site.
Plasmids and Cloning
The cDNA for survivin 2α  was amplified from the EST
clone (Invitrogen) and cloned into the KpnI-BamHI sites
of pcDNA4/TO/myc-HisB (Invitrogen) generating an in-
frame fusion with the C-terminal myc-tag, or into the
KpnI-BamHI sites of pEGFP-N3 generating an in-frame
fusion with the C-terminal GFP tag. The start codon in
both constructs corresponds to the naturally occurring
start codon in the cDNA transcript. The resulting clones
were confirmed by sequencing.
Cell Culture and Transfection
HeLa (cervical adenocarcinoma), Daoy (medulloblast-
oma), Jurkat (acute lymphoblastic leukemia) and MCF-7
(breast adenocarcinoma) cells (ATCC) were grown in
DMEM supplemented with 10% FBS at 37°C, 5% CO2;
Early apoptosis in tumor cells transfected with survivin and survivin 2α Figure 2
Early apoptosis in tumor cells transfected with survivin and survivin 2α . A: Daoy cells were transiently transfected with control 
vector, survivin, survivin 2α , or a combination of survivin and survivin 2α . Apoptosis was measured using Annexin V/PI staining 
24 hours after transfection, in the absence of a cell death stimulus. The results are shown relative to empty vector control. 
Error bars represent standard deviations from triplicate experiments. Results were adjusted for transfection efficiency based 
on parallel transfection with a GFP-expressing plasmid. B: Daoy cells were transiently transfected with control, survivin or sur-
vivin 2α . Apoptosis was measured by Caspase-3 activity following treatment with vincristine. C: HeLa cells were transiently 
transfected with control or GFP-tagged survivin 2α . Electron Microscopy analysis of transfected cells shows a representative 
cell undergoing apoptosis as induced by survivin 2α . Images were taken 12,000× magnification and scale bars are shown.
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U2OS osteosarcoma cells (kindly donated by Dr. Greg
Otterson) were grown in McCoy's 5A medium
supplemented with 10% FBS at 37°C, 5% CO2; RH28
(alveolar rhabdomyosarcoma, kindly donated by Dr.
Steve Qualman) and A549 (lung carcinoma) (ATCC) were
grown in RPMI1640 supplemented with 10% FBS at
37°C, 5% CO2. MCF10-A, a non-transformed breast cell
line (ATCC) was grown in MEGM, Mammary Epithelial
Growth Medium, Serum-free, (Clonetics) supplemented
with 100 ng/ml cholera toxin (Sigma Aldrich) at 37°C,
5% CO2.
Transient transfections were performed using Effectene
transfection reagent (Qiagen) at a DNA: Effectene ratio of
1:10.
Drug Treatment
Induction of apoptosis by vincristine was done by treat-
ment of cells with complete growth medium supple-
Confocal microscopy analysis of survivin 2α  sub-cellular localization Figure 3
Confocal microscopy analysis of survivin 2α  sub-cellular localization. HeLa cells were transfected with GFP-survivin 2α  or 
HcRed survivin, as detailed on the top of the figure. Green pixels correspond to GFP expression, red pixels correspond to 
HcRed expression and blue pixels represent DNA labeled with Hoechst dye. When co-localization of GFP and HcRed occurs 
the pixels are yellow. A: Expression of survivin 2α  at interphase localizes to nuclear and cytoplasmic structures. B: During M-
phase survivin 2α  is excluded from the condensed/dividing chromosomes and is localized in the cytoplasm of the dividing cell. 
C, D, E, F: When co-expressed with survivin, survivin 2α  localization does not change at interphase. During M-phase survivin 
2α  co-localizes with survivin to the centromeres of the dividing chromosomes (D and E), and in the midbody region at cytoki-
nesis (F). Scale bar = 5 µm
GFP-Survivin 2α α α α
HcRed-Survivin
+ + + + + +
++ + + - -
ABC DE F
C3 D3 E3 F3
A2 B2 C2 D2 E2 F2
A1 B1 C1 D1 E1 F1Molecular Cancer 2005, 4:11 http://www.molecular-cancer.com/content/4/1/11
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mented with vincristine sulfate at a final concentration of
2 µM.
RNA isolation and Real Time PCR
RNA was isolated from 106 proliferating cells or frozen
tumor tissue using TriZol reagent (Invitrogen) as recom-
mended by the supplier. Poly(A) RNA was purified using
Oligotex dT kit (Qiagen). 100 ng of poly(A) purified RNA
was used as a template in a reverse transcription reaction
using random hexamers and Omniscript Reverse tran-
scriptase (Qiagen) and performed according to manufac-
turer's instructions. Quantitative real-time PCR reactions
using Taqman probes (FAM/TAMRA) were run in tripli-
cate on an ABI Prism 7700 Real-time PCR machine
(Applied Biosystems). Control GAPDH reactions
(Applied Biosystems) were run to normalize ∆ Ct values.
Relative change was calculated by the comparative CT
method, 2(-∆∆ Ct). The survivin 2α  specific primers consist
of: Forward 5'GCTTTGTTTTGAACTGAGTTGTCAA;
Reverse 5'GCAATGAGGGTGGAAAGCA; and Probe:
6FAM AGATTTGAGTTGCAAAGACACTTAGTAT-
GGGAGGG TAMRA
Apoptosis Assays
Two apoptosis assays were performed: Caspase-3 assay
and Annexin-V FLUOS. For caspase assays 2,000 cells
from each experimental condition were subjected to the
caspase-3 assay, Caspase 3/7 GLO (Promega) and ana-
lyzed on a Victor3 plate reader (Applied Biosystems).
Experiments were performed in triplicate.
Annexin V/propidium iodide staining was carried out
using the Roche Annexin-V-Fluos Staining Kit following
the manufacturer's instructions. Fluorescein and propid-
ium iodide fluorescence measured with a Coulter EPICS
XL flow cytometer. Experiments were performed in
triplicate.
Co-immunoprecipitation of survivin-survivin 2α Figure 4
Co-immunoprecipitation of survivin-survivin 2α . HeLa cells were transfected with constructs encoding tagged forms of survivin 
(Flag) and survivin 2α  (myc). Lysates from transfected cells were subjected to immunoprecipitation with an antibody against the 
Flag epitope. The resulting immunoprecipitated complexes were resolved by SDS-PAGE and subjected to Western blotting. 
The membrane was immunoprobed with an antibody against the myc epitope tag. Survivin 2α -myc is clearly visualized in lysates 
precipitated with a Flag antibody.
Control
IP
Survivin 2α
Flag-survivin
Survivin 2α-myc
Anti-Flag M2
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Microscopy
Proliferating HeLa cells, grown on glass coverslips, were
transiently transfected with a GFP-tagged survivin 2α
expression construct or co-transfected with GFP-tagged
survivin 2α  and HcRed-tagged survivin. 24 hours post-
transfection the cells were fixed in 4% paraformaldehyde
and stained with 50 µg/ml Hoechst dye. Cells were ana-
lyzed on a Zeiss LSM510 META confocal microscope,
using a 63x PlanApochromat objective. For electron
microscopy analysis, proliferating HeLa cells were trans-
fected with GFP-tagged survivin 2α  construct for 12 hours.
The cells were aseptically sorted by FACS based on green
fluorescence from GFP-survivin 2α  for positive and nega-
tive populations. This was done in order to separate an
enriched population that consisted of >90% GFP express-
ing cells. 106 cells for each condition were fixed in 2.5%
gluteraldehyde for 24 hours and processed for EM. For cell
analysis, 10 to 12 fields containing 8–10 cells per field at
a magnification of 3500× were used. At least 100 cells
were counted for each experimental condition and
assigned to categories of healthy or dying based on their
morphological appearance, including nuclear integrity.
Image collection was performed on a Hitachi H-600 trans-
mission electron microscope equipped with a GATAN
image acquisition system.
Co-Immunoprecipitation
HeLa cells transfected with Flag-survivin and survivin-2α
myc were collected in Cell Lysis Buffer (100 mM Tris-HCl
pH8.0, 100 mM NaCl, 0.5% Triton X-100, 0.2 µM PMSF)
and incubated at 4°C for 30 min. The cell lysate was clar-
ified by centrifugation and the clarified supernatant dis-
solved 1:5 in Co-IP buffer (50 mM Tris-HCl pH7.5, 15
mM EGTA, 100 mM NaCl, 0.1% Triton X-100, 1x protease
inhibitors cocktail, 1 mM DTT, 1 mM PMSF). The equiva-
lent of 400 µg of lysate total protein was incubated with 2
µg of anti-Flag M2 antibody at 4°C for 1 h with constant
rotation. As a control the same amount of lysate protein
was incubated in the absence of antibody. Fifty microliters
of agarose-conjugated protein A (Invitrogen) were added
and the mixture incubated for a further hour in the same
conditions. The protein-antibody-protein A complexes
were pulled down by centrifugation and subjected to 3
washes with co-IP buffer. The proteins were analyzed
through electrophoretic separation in a 20% SDS-PAGE,
electroblotted onto nitrocellulose and immunoprobed
with an antibody against myc-tag. Detection was per-
formed using the ECL kit (Amersham). Protein standards
were used for size determination.
Bioinformatics
Subcellular localization predicted by PSORTII program.
Coiled-Coil domain predicted by Coils and PairCoil
programs
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